IMab (IMAB)
(Delayed Data from NSDQ)
$1.72 USD
+0.14 (8.86%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $1.71 -0.01 (-0.58%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IMAB 1.72 +0.14(8.86%)
Will IMAB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IMAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMAB
Here's Why IMab Sponsored ADR (IMAB) is Poised for a Turnaround After Losing 26.8% in 4 Weeks
I-Mab (IMAB) Down After Partner AbbVie Revises Partnership Deal
IMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for IMAB
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476M
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
I-Mab Biopharma: Innovating Cancer Treatments
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
I-Mab names Phillip Dennis, MD, PhD, as Chief Medical Officer